|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hensing T, Chawla A, Batra R and Salgia R:
A personalized treatment for lung cancer: Molecular pathways,
targeted therapies, and genomic characterization. Adv Exp Med Biol.
799:85–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nanavaty P, Alvarez MS and Alberts WM:
Lung cancer screening: Advantages, controversies, and applications.
Cancer Control. 21:9–14. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gainor JF, Tan DS, De Pas T, Solomon BJ,
Ahmad A, Lazzari C, de Marinis F, Spitaleri G, Schultz K, Friboulet
L, et al: Progression-free and overall survival in Alk-positive
NSCLC patients treated with sequential crizotinib and ceritinib.
Clin Cancer Res. 21:2745–2752. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu C, Shi X, Wang L, Wu Y, Jin F, Bai C
and Song Y: SUZ12 is involved in progression of non-small cell lung
cancer by promoting cell proliferation and metastasis. Tumour Biol.
35:6073–6082. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang FQ, Yang WT, Duan SZ, Xia YC, Zhu RY
and Chen YB: JAK2 inhibitor TG101348 overcomes erlotinib-resistance
in non-small cell lung carcinoma cells with mutated EGF receptor.
Oncotarget. 6:14329–14343. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nishinaka T, Miura T, Sakou M, Hidaka C,
Sasaoka C, Okamura A, Okamoto A and Terada T: Down-regulation of
aldo-keto reductase AKR1B10 gene expression by a phorbol ester via
the ERK/c-Jun signaling pathway. Chem Biol Interact. 234:274–281.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cao D, Fan ST and Chung SS: Identification
and characterization of a novel human aldose reductase-like gene. J
Biol Chem. 273:11429–11435. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Penning TM: AKR1B10: A new diagnostic
marker of non-small cell lung carcinoma in smokers. Clin Cancer
Res. 11:1687–1690. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Fukumoto S, Yamauchi N, Moriguchi H, Hippo
Y, Watanabe A, Shibahara J, Taniguchi H, Ishikawa S, Ito H,
Yamamoto S, et al: Overexpression of the aldo-keto reductase family
protein AKR1B10 is highly correlated with smokers' non-small cell
lung carcinomas. Clin Cancer Res. 11:1776–1785. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kang MW, Lee ES, Yoon SY, Jo J, Lee J, Kim
HK, Choi YS, Kim K, Shim YM, Kim J and Kim H: AKR1B10 is associated
with smoking and smoking-related non-small-cell lung cancer. J Int
Med Res. 39:78–85. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chung YT, Matkowskyj KA, Li H, Bai H,
Zhang W, Tsao MS, Liao J and Yang GY: Overexpression and oncogenic
function of aldo-keto reductase family 1B10 (AKR1B10) in pancreatic
carcinoma. Mod Pathol. 25:758–766. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tarca AL, Lauria M, Unger M, Bilal E, Boue
S, Kumar Dey K, Hoeng J, Koeppl H, Martin F, Meyer P, et al:
Strengths and limitations of microarray-based phenotype prediction:
Lessons learned from the IMPROVER diagnostic signature challenge.
Bioinformatics. 29:2892–2899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang C, Verhulst S, Shen Y, Bu Y, Cao Y,
He Y, Wang Y, Huang D, Cai C, Rao K, et al: AKR1B10 promotes breast
cancer metastasis through integrin α5/δ-catenin mediated
FAK/Src/Rac1 signaling pathway. Oncotarget. 7:43779–43791. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zemanova L, Hofman J, Novotna E, Musilek
K, Lundova T, Havrankova J, Hostalkova A, Chlebek J, Cahlikova L
and Wsol V: Flavones inhibit the activity of AKR1B10, a promising
therapeutic target for cancer treatment. J Nat Prod. 78:2666–2674.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cao Z, Zhou B, Chen X, Huang D, Zhang X,
Wang Z, Huang H, Wang Y and Cao D: Statil suppresses cancer cell
growth and proliferation by the inhibition of tumor marker AKR1B10.
Anticancer Drugs. 25:930–937. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Balendiran GK, Martin HJ, El-Hawari Y and
Maser E: Cancer biomarker AKR1B10 and carbonyl metabolism. Chem
Biol Interact. 178:134–137. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Huang L, He R, Luo W, Zhu YS, Li J, Tan T,
Zhang X, Hu Z and Luo D: Aldo-Keto reductase family 1 member B10
inhibitors: Potential drugs for cancer treatment. Recent Pat
Anticancer Drug Discov. 11:184–196. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhong L, Liu Z, Yan R, Johnson S, Zhao Y,
Fang X and Cao D: Aldo-keto reductase family 1 B10 protein
detoxifies dietary and lipid-derived alpha, beta-unsaturated
carbonyls at physiological levels. Biochem Biophys Res Commun.
387:245–250. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ma J, Yan R, Zu X, Cheng JM, Rao K, Liao
DF and Cao D: Aldo-keto reductase family 1 B10 affects fatty acid
synthesis by regulating the stability of acetyl-CoA
carboxylase-alpha in breast cancer cells. J Biol Chem.
283:3418–3423. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Harper JW, Adami GR, Wei N, Keyomarsi K
and Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent
inhibitor of G1 cyclin-dependent kinases. Cell. 75:805–816. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang XQ, Yang CY, Rao XF and Xiong JP:
Plumbagin shows anti-cancer activity in human breast cancer cells
by the upregulation of p53 and p21 and suppression of G1 cell cycle
regulators. Eur J Gynaecol Oncol. 37:30–35. 2016.PubMed/NCBI
|
|
24
|
Alldridge LC and Bryant CE: Annexin 1
regulates cell proliferation by disruption of cell morphology and
inhibition of cyclin D1 expression through sustained activation of
the ERK1/2 MAPK signal. Exp Cell Res. 290:93–107. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Osaki LH and Gama P: MAPKs and signal
transduction in the control of gastrointestinal epithelial cell
proliferation and differentiation. Int J Mol Sci. 14:10143–10161.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li J, Guo Y, Duan L, Hu X, Zhang X, Hu J,
Huang L, He R, Hu Z, Luo W, et al: AKR1B10 promotes breast cancer
cell migration and invasion via activation of ERK signaling.
Oncotarget. 8:33694–33703. 2017.PubMed/NCBI
|
